Amedisys (AMED) Tops Q4 EPS by 5c

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $337.3 million versus the consensus estimate of $322.01 million.

Earnings before interest, taxes, depreciation and amortization attributable to continuing operations (“EBITDA”) of $27.6 million compared to $22.9 million in 2014.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance
• Alcoa prices $2.6B in senior notes to fund South32 asset deal